Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Biopharma Operating Segment by Year
Biopharma Operating Segment — Segment Pretax Income / Earnings ($M) ($M)
Pfizer Biopharma Operating Segment: $29,342M in FY2025, up 4.9% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Granular segment expense disaggregation adopted under FASB ASU 2023-07 plus corporate reconciling items not in DB segment_values.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biopharma Operating Segment — Segment Pretax Income / Earnings ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 29,342 | +4.9% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 27,969 | +77.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 15,767 | -67.1% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 47,939 | +17.9% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 40,647 | +49.5% | Form 10-K (filed 2024-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 27,191 | +11.4% | Form 10-K (filed 2023-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 24,419 | +2.9% | Form 10-K (filed 2022-02-24) ↗ |
| FY2018 | Dec 31, 2018 | 23,738 | +7.0% | Form 10-K (filed 2020-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 22,194 | – | Form 10-K (filed 2020-02-27) ↗ |
Breakdown
What makes up biopharma Operating Segment
- Biopharma Segment — Cost of sales (ASU 2023-07 significant expense) ($M)13,505 · FY2025
- Biopharma Segment — Selling, informational & administrative expenses ($M)9,637 · FY2025
- Biopharma Segment — Research & development expenses ($M)9,183 · FY2025
- Biopharma Segment — Acquired in-process R&D (IPR&D) ($M)113 · FY2025
- Biopharma Segment — Other (income)/deductions — net ($M)581 · FY2025
- Biopharma Segment — Depreciation & amortization ($M)1,379 · FY2025
- Other Business Activities (PC1, Pfizer Ignite) — Revenues ($M)1,380 · FY2025
- Other Business Activities (PC1, R&D platforms & corporate research) — Pretax loss ($M)-8,199 · FY2025
- Corporate / Unallocated Reconciling Item — Intangible amortization pretax impact ($M)-4,874 · FY2025
- Corporate / Unallocated Reconciling Item — Acquisition-related costs pretax impact ($M)-1,285 · FY2025
- Corporate / Unallocated Reconciling Item — Certain significant & unallocated items ($M)-7,464 · FY2025
- Amortization of intangible assets unassociated with segments ($M)4,874 · FY2025
Cite this data
StockData. (2026). Pfizer Biopharma Operating Segment ($M), annual FY2017–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/seg-ebt-biopharma
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.